Transzvénás, subcutan patch nélküli pacemaker-cardioverter-defibrillátorokkal szerzett tapasztalataink.

Translated title of the contribution: Experience with a transvenous pacemaker-cardioconverter-defibrillator without subcutaneous patch

T. Gyöngy, B. Merkely, J. Tenczer, T. Vecsey, F. Horkay, I. Kalmár, I. Matkó, F. Solti, E. Bodor

Research output: Contribution to journalArticle

Abstract

Sudden cardiac death caused by malignant ventricular arrhythmias is one of the main causes of cardiovascular mortality. Implantation of cardioverter-defibrillators has resulted in the reduction of the incidence of sudden cardiac death caused by malignant ventricular arrhythmias from the yearly 10-30% to 1%. For the very first time in Hungary, the authors applied only transvenous lead configuration for automatic cardioverter defibrillators in three patients. The indications of the implantation were ventricular fibrillation in one case, ventricular tachycardias refractory to drug treatment in two cases. Ventricular arrhythmias were secondary to coronary heart disease in two patients, dilatative cardiomyopathy in one patient. Preoperative, intraoperative and postoperative electrophysiological studies were regularly taken. Using Biotronik Phylax 03 device with a right ventricular electrode and a superior vena cava electrode and without subcutaneous patch the intraoperative defibrillation thresholds were 6, 11 and 12 J respectively. The fractally iridium coating increases the surface of the electrodes that has a very good effect on defibrillation threshold. During a mean follow-up of six months the occurring spontaneous ventricular arrhythmias (1 ventricular fibrillation and 5 ventricular tachycardias) were terminated by Phylax 03 with cardioversion-defibrillation or overdrive stimulation. The authors' results of intraoperative testing and clinical experiences show that the Phylax 03 biphasic system due to low defibrillation thresholds without subcutaneous patch can safely be applied with only transvenous implant technique in patients with major ventricular arrhythmias to prevent sudden cardiac death and to terminate ventricular tachycardia.

Original languageHungarian
Pages (from-to)299-304
Number of pages6
JournalOrvosi Hetilap
Volume136
Issue number6
Publication statusPublished - Feb 5 1995

Fingerprint

Defibrillators
Cardiac Arrhythmias
Sudden Cardiac Death
Ventricular Tachycardia
Electrodes
Ventricular Fibrillation
Iridium
Electric Countershock
Superior Vena Cava
Hungary
Cardiomyopathies
Coronary Disease
Equipment and Supplies
Mortality
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transzvénás, subcutan patch nélküli pacemaker-cardioverter-defibrillátorokkal szerzett tapasztalataink. / Gyöngy, T.; Merkely, B.; Tenczer, J.; Vecsey, T.; Horkay, F.; Kalmár, I.; Matkó, I.; Solti, F.; Bodor, E.

In: Orvosi Hetilap, Vol. 136, No. 6, 05.02.1995, p. 299-304.

Research output: Contribution to journalArticle

Gyöngy, T, Merkely, B, Tenczer, J, Vecsey, T, Horkay, F, Kalmár, I, Matkó, I, Solti, F & Bodor, E 1995, 'Transzvénás, subcutan patch nélküli pacemaker-cardioverter-defibrillátorokkal szerzett tapasztalataink.', Orvosi Hetilap, vol. 136, no. 6, pp. 299-304.
Gyöngy, T. ; Merkely, B. ; Tenczer, J. ; Vecsey, T. ; Horkay, F. ; Kalmár, I. ; Matkó, I. ; Solti, F. ; Bodor, E. / Transzvénás, subcutan patch nélküli pacemaker-cardioverter-defibrillátorokkal szerzett tapasztalataink. In: Orvosi Hetilap. 1995 ; Vol. 136, No. 6. pp. 299-304.
@article{56a82e24a87c45f9ad82231de6bfd465,
title = "Transzv{\'e}n{\'a}s, subcutan patch n{\'e}lk{\"u}li pacemaker-cardioverter-defibrill{\'a}torokkal szerzett tapasztalataink.",
abstract = "Sudden cardiac death caused by malignant ventricular arrhythmias is one of the main causes of cardiovascular mortality. Implantation of cardioverter-defibrillators has resulted in the reduction of the incidence of sudden cardiac death caused by malignant ventricular arrhythmias from the yearly 10-30{\%} to 1{\%}. For the very first time in Hungary, the authors applied only transvenous lead configuration for automatic cardioverter defibrillators in three patients. The indications of the implantation were ventricular fibrillation in one case, ventricular tachycardias refractory to drug treatment in two cases. Ventricular arrhythmias were secondary to coronary heart disease in two patients, dilatative cardiomyopathy in one patient. Preoperative, intraoperative and postoperative electrophysiological studies were regularly taken. Using Biotronik Phylax 03 device with a right ventricular electrode and a superior vena cava electrode and without subcutaneous patch the intraoperative defibrillation thresholds were 6, 11 and 12 J respectively. The fractally iridium coating increases the surface of the electrodes that has a very good effect on defibrillation threshold. During a mean follow-up of six months the occurring spontaneous ventricular arrhythmias (1 ventricular fibrillation and 5 ventricular tachycardias) were terminated by Phylax 03 with cardioversion-defibrillation or overdrive stimulation. The authors' results of intraoperative testing and clinical experiences show that the Phylax 03 biphasic system due to low defibrillation thresholds without subcutaneous patch can safely be applied with only transvenous implant technique in patients with major ventricular arrhythmias to prevent sudden cardiac death and to terminate ventricular tachycardia.",
author = "T. Gy{\"o}ngy and B. Merkely and J. Tenczer and T. Vecsey and F. Horkay and I. Kalm{\'a}r and I. Matk{\'o} and F. Solti and E. Bodor",
year = "1995",
month = "2",
day = "5",
language = "Hungarian",
volume = "136",
pages = "299--304",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "6",

}

TY - JOUR

T1 - Transzvénás, subcutan patch nélküli pacemaker-cardioverter-defibrillátorokkal szerzett tapasztalataink.

AU - Gyöngy, T.

AU - Merkely, B.

AU - Tenczer, J.

AU - Vecsey, T.

AU - Horkay, F.

AU - Kalmár, I.

AU - Matkó, I.

AU - Solti, F.

AU - Bodor, E.

PY - 1995/2/5

Y1 - 1995/2/5

N2 - Sudden cardiac death caused by malignant ventricular arrhythmias is one of the main causes of cardiovascular mortality. Implantation of cardioverter-defibrillators has resulted in the reduction of the incidence of sudden cardiac death caused by malignant ventricular arrhythmias from the yearly 10-30% to 1%. For the very first time in Hungary, the authors applied only transvenous lead configuration for automatic cardioverter defibrillators in three patients. The indications of the implantation were ventricular fibrillation in one case, ventricular tachycardias refractory to drug treatment in two cases. Ventricular arrhythmias were secondary to coronary heart disease in two patients, dilatative cardiomyopathy in one patient. Preoperative, intraoperative and postoperative electrophysiological studies were regularly taken. Using Biotronik Phylax 03 device with a right ventricular electrode and a superior vena cava electrode and without subcutaneous patch the intraoperative defibrillation thresholds were 6, 11 and 12 J respectively. The fractally iridium coating increases the surface of the electrodes that has a very good effect on defibrillation threshold. During a mean follow-up of six months the occurring spontaneous ventricular arrhythmias (1 ventricular fibrillation and 5 ventricular tachycardias) were terminated by Phylax 03 with cardioversion-defibrillation or overdrive stimulation. The authors' results of intraoperative testing and clinical experiences show that the Phylax 03 biphasic system due to low defibrillation thresholds without subcutaneous patch can safely be applied with only transvenous implant technique in patients with major ventricular arrhythmias to prevent sudden cardiac death and to terminate ventricular tachycardia.

AB - Sudden cardiac death caused by malignant ventricular arrhythmias is one of the main causes of cardiovascular mortality. Implantation of cardioverter-defibrillators has resulted in the reduction of the incidence of sudden cardiac death caused by malignant ventricular arrhythmias from the yearly 10-30% to 1%. For the very first time in Hungary, the authors applied only transvenous lead configuration for automatic cardioverter defibrillators in three patients. The indications of the implantation were ventricular fibrillation in one case, ventricular tachycardias refractory to drug treatment in two cases. Ventricular arrhythmias were secondary to coronary heart disease in two patients, dilatative cardiomyopathy in one patient. Preoperative, intraoperative and postoperative electrophysiological studies were regularly taken. Using Biotronik Phylax 03 device with a right ventricular electrode and a superior vena cava electrode and without subcutaneous patch the intraoperative defibrillation thresholds were 6, 11 and 12 J respectively. The fractally iridium coating increases the surface of the electrodes that has a very good effect on defibrillation threshold. During a mean follow-up of six months the occurring spontaneous ventricular arrhythmias (1 ventricular fibrillation and 5 ventricular tachycardias) were terminated by Phylax 03 with cardioversion-defibrillation or overdrive stimulation. The authors' results of intraoperative testing and clinical experiences show that the Phylax 03 biphasic system due to low defibrillation thresholds without subcutaneous patch can safely be applied with only transvenous implant technique in patients with major ventricular arrhythmias to prevent sudden cardiac death and to terminate ventricular tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0029636184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029636184&partnerID=8YFLogxK

M3 - Article

VL - 136

SP - 299

EP - 304

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 6

ER -